Type 2 diabetes mellitus and coronary heart disease;Diabetes mellitus typ 2 und koronare herzkrankheit

Schweizerische Medizinische Wochenschrift

Volumn 129, Issue 18, 1999, Pages 700-706

  Brandle M ^a   Amann, F W ^a   Salomon, F ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Medizinische Klinik Zurich   (Switzerland)

Author keywords

Acute myocardial infarction; Coronary heart disease; Prevention; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; COMORBIDITY; CORONARY RISK; FIBRINOLYTIC THERAPY; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK MANAGEMENT;

CAUSE OF DEATH; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS;

EID: 0033535789     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Neil HA, Gatling W, Mather HM, Thompson AV, Thorogood M, Fowler GH, et al. The Oxford Community Diabetes Study: evidence for an increase in the prevalence of known diabetes in Great Britain. Diabet Med 1987;4:539-43.
2. Benett PH, Bogardus C, Tuomilehto J, Zimmet P. Epidemiology and natural history of NIDDM: non-obese and obese. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors. International Textbook of Diabetes mellitus. 2nd ed.: John Wiley & Sons; 1997. p. 147-76.
3. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 1997;350(Suppl 1):SI4-9.
4. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
5. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979;59:8-13.
6. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3:463-524.
7. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
8. Laakso M, Ronnemaa T, Lehto S, Puukka P, Kallio V, Pyörälä K. Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations? Diabetologia 1995;38:487-93.
9. Raman M, Nesto RW. Heart disease in diabetes mellitus. Endocrinol Metab Clin North Am 1996;25:425-38.
10. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265:627-31.
11. Manson JE, Colditz CA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151: 1141-7.
12. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617-21.
13. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
14. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992;85: 1254-64.
15. Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Myocardial Infarction Data Acquisition System Study Group. Am Heart J 1995;130:51-8.
16. Herlitz J, Karlson BW, Edvardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology 1992;80:237-45.
17. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 1:69-75.
18. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Reviews 1997;5:294-315.
19. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998; 316:823-8.
20. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68.
21. Sewdarsen M, Vythilingum S, Jialal I, Becker PJ. Prognostic importance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction. QJ Med 1989;71:461-6.
22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:183-97.
23. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: diagnosis and classification of diabetes mellitus - provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-53.
24. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343: 155-8.
25. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57-65.
26. Malmberg K for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997; 314:1512-5.
27. Webster MW, Scott RS. What cardiologists need to know about diabetes. Lancet 1997;350(Suppl 1):SI23-8.
28. Nattrass M. Managing diabetes after myocardial infarction. Br Med J 1997;314:1497.
29. Muhlhauser I, Sawicki PT, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia 1997;40:1492-3.
30. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
31. Yudkin JS. Managing the diabetic patient with acute myocardial infarction. Diabet Med 1998;15:276-81.
32. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11:43-50.
33. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985;6:199-226.
34. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123:358-67.
35. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76.
36. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96:4239-45.
37. Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation 1998;97:12-5.
38. American Diabetes Association: Standards of medical care of patients with diabetes mellitus. Diabetes Care 1998;(Suppl. 1):S23-S33.
39. Tatti P, Pahor M, Byington RP, Di-Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
40. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
41. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158:134-40.
42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
43. MacDonald TM, Butler R, Newton RW, Morris AD, for the DARTS/MEMO Collaboration. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? Diabet Med 1998;15:282-9.
44. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
45. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
46. Goldberg RB, Mellies JM, Sacks FM, Moyé LA, Howard BV, Howard-WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-19.
47. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
48. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
49. Jonas M, Reicher-Reiss H, Boyko V, Shotan A, Mandelzweig L, Goldbourt U, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996;77:1273-7.
50. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Braunwald E, on behalf of the SAVE Investigators. Effects of captopril on ischemic effects after myocardial infarction. Circulation 1994;90:1731-8.